Bayer and DelSiTech Ltd., a Finnish drug delivery technology and drug development company, have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in ophthalmology.
Keep updated with our latest news.
Bayer’s researchers have new ideas for developing active medications and clinician researchers like us can screen and select patients based on these ideas who may benefit.
The ‘Grants4Apps Accelerator’ gives innovators a chance to learn and fine-tune everything it takes to successfully market their ideas.
A growing and aging world population, limited natural resources and the impact of climate change make it important to improve crop yield, stress tolerance and nutritional value while minimizing environmental impact.
We thought we had a mature understanding of our business model – and emerged with a model that is actually viable for a startup company.
I expect immunoncology to become established as an integral part of cancer treatment over the next few years and to offer real prospects.
Startups whose work is related to Bayer’s pharmaceutical R&D focus are offered rental office and lab space on the company’s campus in Berlin. Working side by side has inspired fruitful scientific discussion.
Our scientific successes are intended to help improve people’s lives.
At the same time, our innovations form the basis for sustainable and profitable business activity.